Human Papillomavirus (HPV) Vaccine Market Report 2026

Human Papillomavirus (HPV) Vaccine Market Overview

• Human Papillomavirus (HPV) Vaccine market size has reached to $6.57 billion in 2025 • Expected to grow to $12.17 billion in 2030 at a compound annual growth rate (CAGR) of 13.2% • Growth Driver: Rising Prevalence Of HPV-Related Diseases Sparks Surge In Human Papillomavirus (HPV) Vaccine Market Growth • Market Trend: Innovative Awareness Campaigns Drive HPV Vaccination Initiatives In India • North America was the largest region in 2025.

What Is Covered Under Human Papillomavirus (HPV) Vaccine Market?

Human Papillomavirus (HPV) Vaccine refers to a vaccine that aids in preventing specific strains of human papillomavirus (HPV) from infecting the body. HPV vaccines treat most cervical, vaginal, and vulvar cancer occurrences. The main human papillomavirus (HPV) vaccine types are tetravalent, nonavalent, and bivalent. Tetravalent refers to a vaccine that activates the body's defenses against four distinct antigens, such as four distinct viruses or other microbes, to produce an immunological response. The various disease indications a are cervical cancer, anal cancer, vulvar and vaginal cancer, penile cancer, oropharyngeal cancer, and others and vaccines are channeled through hospital and retail pharmacies, government suppliers, and others. The various industry verticals are public and private alliance, government entities, physicians, and others.

What Is The Human Papillomavirus (HPV) Vaccine Market Growth Forecast?

The human papillomavirus (hpv) vaccine market size is expected to see rapid growth in the next few years. It will grow to $12.17 billion in 2030 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to increasing adoption of nonavalent vaccines, expansion of public-private healthcare partnerships, growth in awareness campaigns, technological advancements in vaccine delivery, rising investments in preventive healthcare. Major trends in the forecast period include increased hpv vaccination awareness, government immunization programs, expansion in emerging markets, development of next-generation hpv vaccines, partnerships between pharma companies and healthcare providers.

Global Human Papillomavirus (HPV) Vaccine Market Segmentation

1) By Type: Tetravalent, Nonavalent, Bivalent 2) By Disease Indication: Cervical Cancer, Anal Cancer, Vulvar And Vaginal Cancer, Penile Cancer, Oropharyngeal Cancer, Other Indications 3) By Distribution Channel: Hospital And Retail Pharmacies, Government Suppliers, Other Channels 4) By Industry Vertical: Public And Private Alliance, Government Entities, Physicians, Other Industries

What Is The Driver Of The Human Papillomavirus (HPV) Vaccine Market?

The increased prevalence of HPV-related diseases is expected to propel the growth of the human papillomavirus (HPV) vaccine market going forward. HPV-related diseases are viral infections that frequently result in warts on the skin or mucous membranes. The HPV vaccination specifically targets the HPV subtypes. The HPV vaccine controls the risk of HPV infection and recurrent diseases. For Instance, in February 2023, according to the National Cancer Institute, a US-based Department of Health and Human Services, around 13,960 American women are anticipated to have an aggressive cervical cancer diagnosis, and 4,310 fatalities from this illness are expected in 2023 in the US. Further, 7.7 per 100,000 women per year new cases of cervical cancer were diagnosed, with an annual death rate of 2.2 per 100,000 females. Therefore, the increased prevalence of HPV-related diseases is driving the growth of the human papillomavirus (HPV) vaccine industry.

Key Players In The Global Human Papillomavirus (HPV) Vaccine Market

Major companies operating in the human papillomavirus (hpv) vaccine market are Merck & Co Inc, GlaxoSmithKline plc, Serum Institute of India Pvt Ltd, Walvax Biotechnology Co Ltd, Beijing Wantai Biological Pharmacy Enterprise Co Ltd, Xiamen Innovax Biotech Co Ltd, Bharat Biotech International Ltd, Shanghai Zerun Biotech Co Ltd, Recbio Biotech, Yuxi Zerun Biotechnology Co Ltd, Innovax, Biofarma Co, Incepta Pharmaceuticals, PT Bio Farma, Instituto Butantan, Sinergium Biotech, BioMed Vaccine Technologies, Vaxart Inc., GeoVax, Recbio

Global Human Papillomavirus (HPV) Vaccine Market Trends and Insights

Major companies operating in the human papillomavirus (HPV) vaccine market are focusing on developing innovation, such as awareness campaigns to educate communities about the benefits of vaccination. Awareness campaigns are strategic efforts designed to educate and inform a specific audience or the general public about a particular issue, cause, product, or service. For instance, in January 2023, the Family Planning Association of India, an India-based charity, launched a vaccine drive against cervical cancer, targeting girls aged 9 to 14 years. A nationwide HPV vaccination drive is underway to protect girls and women from cervical cancer. The campaign will use a quadrivalent vaccine targeting key strains of the virus. Aiming to vaccinate around 50 million girls, the initiative focuses on raising awareness and improving access in both urban and rural areas.

What Are Latest Mergers And Acquisitions In The Human Papillomavirus (HPV) Vaccine Market?

In August 2023, MSD, a U.S.-based provider of vaccines and medicines operating globally under the Merck & Co., Inc. umbrella, partnered with Bio Farma to locally produce the 4-valent HPV vaccine under the name NUSAGARD. With this partnership, MSD aims to transfer its HPV vaccine technology to expand local manufacturing capacity, thereby improving vaccine accessibility and supply for Indonesia’s national immunization program. Bio Farma is an Indonesia-based provider of end-to-end pharmaceutical services, including vaccine research, development, manufacturing, and distribution.

Regional Insights

North America was the largest region in the human papillomavirus (HPV) vaccine market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Human Papillomavirus (HPV) Vaccine Market?

The human papillomavirus (HPV) vaccine market consists of sales of gardasil 9, gardasil, and cervarix. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Human Papillomavirus (HPV) Vaccine Market Report 2026?

The human papillomavirus (hpv) vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the human papillomavirus (hpv) vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.